Medivation Inc (MDVN) 104.71 $MDVN
Critical Alerts For Interxion, Amedisys, 3M, Medivation and Dominos Pizza Released By InvestorsObserver
PR Newswire - Thu Feb 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for INXN, AMED, MMM, MDVN and DPZ.
MDVN: 104.71 (+0.67), MMM: 165.94 (+0.03), DPZ: 100.00 (-0.56), INXN: 32.04 (+0.14), AMED: 28.62 (+0.16)
Medivation Announces Fourth Quarter and Year-End 2014 Financial Results Teleconference on February 25, 2015
Marketwired - Wed Feb 11, 3:10PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss fourth quarter and year-end 2014 financial results and provide a general business update on February 25, 2015 at 4:30 p.m. Eastern Time. A press release for the fourth quarter and year-end of 2014 will be released after markets close on February 25, 2015.
MDVN: 104.71 (+0.67)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 104.71 (+0.67), BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), TGTX: 13.13 (-0.19), TKMR: 21.45 (-0.22), ANAC: 40.76 (-0.07), PBYI: 205.26 (+2.75), REGN: 402.40 (+0.66)
Today's Review on Biotech Equities - Vertex Pharma, Alexion Pharma, Arrowhead Research, Medivation, and Incyte
PR Newswire - Tue Feb 10, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 104.71 (+0.67), VRTX: 113.66 (+4.03), ARWR: 6.77 (+0.21), INCY: 75.94 (+0.28), ALXN: 182.29 (+6.02)
Coverage of Biotech Equities -- Amarin, Cytori Therapeutics, Medivation, Sangamo BioSciences, and Immunomedics
PR Newswire - Thu Feb 05, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Cytori Therapeutics Inc. (NASDAQ: CYTX), Medivation Inc. (NASDAQ: MDVN), Sangamo BioSciences Inc. (NASDAQ: SGMO), and Immunomedics Inc. (NASDAQ: IMMU). Free research report on Amarin can be accessed at http://get.Investor-Edge.com/pdf/?c=Amarin&am...amp;s=AMRN. The US markets on Wednesday, February 04, 2015, mostly ended on a negative note as the Dow Jones Industrial Average finished at 17,673.02, up 0.04% and the NASDAQ Composite closed at 4,716.70, down 0.23%. The S&P 500 finished the session 0.42% lower at 2,041.51. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, whereas the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
MDVN: 104.71 (+0.67), IMMU: 3.84 (unch), CYTX: 0.47 (unch), AMRN: 1.18 (unch), SGMO: 15.40 (+0.14)
Valeant Agrees To Buy Dendreon's Provenge
at Investor's Business Daily - Fri Jan 30, 10:39AM CST
Canadian drugmaker and serial acquirer Valeant Pharmaceuticals International (VRX) entered into a tentative agreement to buy the assets of bankrupt biotech Dendreon late Thursday, including Dendreon's controversial "cancer vaccine" Provenge. Valeant...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), VRX: 167.00 (-0.50), NVS: 102.20 (-0.17)
Franchise Fortunes Mark Shifts In Consensus For Marketed Products
EP Vantage - Seeking Alpha - Thu Jan 29, 3:48PM CST
Sofosbuvir is the gift that keeps on giving for Gilead Sciences (NASDAQ: GILD ). The performance of the hepatitis C franchise it has built around Sovaldi and Harvoni has had euphoric sell-side analysts giving it the biggest upgrade of any marketed...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), SNY: 49.42 (+0.82)
Insider Buys And Sells: OPKO Health, Burlington Stores
Asif Suria - Seeking Alpha - Sun Jan 25, 10:28AM CST
Welcome to edition 240 of Insider Weekends. Insider buying declined sharply last week with insiders buying just $16.43 million of stock compared to $40.18 million in the week prior. Selling on the other hand increased with insiders selling $936.53...
MDVN: 104.71 (+0.67), NOW: 77.55 (+1.60), CMC: 15.40 (+0.37), SAR: 15.78 (+0.23), OPK: 13.80 (-0.28), DAL: 44.50 (-0.31), LNG: 74.48 (+0.90), DIS: 104.17 (+0.59), BURL: 51.91 (-0.56), URI: 92.98 (+1.41)
Medivation and Astellas Report TERRAIN Data on Xtandi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 3:20PM CST
Medivation Inc. (MDVN) and partner Astellas Pharma Inc.'s (ALPMY) Xtandi met the primary endpoint in a phase II study (TERRAIN) conducted in metastatic prostate cancer patients.
MDVN: 104.71 (+0.67), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30)
Medivation's Xtandi Easily Outperforms Casodex In Key Trial
Stock Doctor - Seeking Alpha - Fri Jan 23, 11:06AM CST
I have written many articles about Medivation (NASDAQ: MDVN ) and why I believe their prostate cancer drug Xtandi (Enzalutamide) is going to be a multi-billion dollar drug. It is already being prescribed at a run rate of $1.2B in 2015. Medivation's...
MDVN: 104.71 (+0.67)
InsiderInsights.com Daily Round Up 1/22/15: SWN, CBIN, OPK, RWC
InsiderInsights - at Seeking Alpha - Fri Jan 23, 8:53AM CST
AFAM: 30.88 (+0.37), SRE: 105.56 (-1.11), SHLD: 35.70 (+2.32), OWW: 11.68 (-0.04), DLPH: 78.70 (+0.64), K: 63.20 (-0.10), MDVN: 104.71 (+0.67), NOW: 77.55 (+1.60), SNCR: 43.89 (+1.06), OPK: 13.80 (-0.28), ARR: 3.13 (unch), RWC: 5.82 (+0.06), CDNA: 6.30 (-0.14), CBIN: 27.23 (+0.08), SWN: 27.36 (+0.51), PAYC: 32.37 (-0.71)
After Yesterday's Decline of 3.90%, Medivation Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jan 22, 4:30PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $103.46 to a high of $109.60. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $105.36 on volume of 3.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MDVN: 104.71 (+0.67)
Medivation (MDVN) Weak On High Volume Today
at The Street - Thu Jan 22, 9:02AM CST
Trade-Ideas LLC identified Medivation (MDVN) as a weak on high relative volume candidate
MDVN: 104.71 (+0.67)
Xtandi successful in Phase 2 study
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 7:34AM CST
MDVN: 104.71 (+0.67), AZN: 69.96 (+0.20)
Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase in PFS as Compared to Bicalutamide in Metastatic Prostate Cancer
Marketwired - Thu Jan 22, 6:00AM CST
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced topline results from the Phase 2 TERRAIN trial comparing enzalutamide with bicalutamide in men with metastatic castration-resistant prostate cancer. The study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival (PFS) for enzalutamide compared to bicalutamide (Hazard Ratio = 0.44; 95% Confidence Interval, 0.34-0.57; p < 0.0001). Median PFS was 15.7 months in the enzalutamide group compared to 5.8 months in the bicalutamide group.
MDVN: 104.71 (+0.67)
Johnson & Johnson Finding Growth A Little Harder Now
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 21, 7:25AM CST
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18)
Johnson & Johnson Overcomes Threats from Competitors, Delivers Solid Quarterly Results
Todd Campbell, The Motley Fool - Motley Fool - Tue Jan 20, 1:01PM CST
Source: Johnson & Johnson Despite two of Johnson & Johnson 's best-selling drugs facing stiffer competition, the company still managed to deliver encouraging sales and earnings during the fourth quarter. After adjusting for currency...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00)
J&J Earnings Beat But Sales, Guidance Miss
at Investor's Business Daily - Tue Jan 20, 10:20AM CST
Medical giant Johnson & Johnson (JNJ) beat analysts' Q4 profit estimates Tuesday but missed on the topline and offered weak guidance, sending the stock down more than 3% in morning trading. J&J said that its Q4 earnings excluding one-time items rose...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00), SYK: 94.51 (+1.14)
Eli Lilly Has 'Turned The Corner,' Upgraded
at Investor's Business Daily - Thu Jan 15, 10:02AM CST
Goldman Sachs upgraded Eli Lilly (LLY) to neutral Thursday, saying the big pharma had "turned the corner" after falling hard off the patent cliff. But the investment bank downgraded Johnson & Johnson, citing increasing drug competition. "We believe...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
Look for Shares of Medivation to Potentially Pullback after Yesterday's 1.94% Rise
Comtex SmarTrend(R) - Tue Jan 13, 4:29PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $105.18 to a high of $109.99. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $105.18 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 104.71 (+0.67)
Critical Alerts For Interxion, Amedisys, 3M, Medivation and Dominos Pizza Released By InvestorsObserver
PR Newswire - Thu Feb 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for INXN, AMED, MMM, MDVN and DPZ.
MDVN: 104.71 (+0.67), MMM: 165.94 (+0.03), DPZ: 100.00 (-0.56), INXN: 32.04 (+0.14), AMED: 28.62 (+0.16)
Medivation Announces Fourth Quarter and Year-End 2014 Financial Results Teleconference on February 25, 2015
Marketwired - Wed Feb 11, 3:10PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss fourth quarter and year-end 2014 financial results and provide a general business update on February 25, 2015 at 4:30 p.m. Eastern Time. A press release for the fourth quarter and year-end of 2014 will be released after markets close on February 25, 2015.
MDVN: 104.71 (+0.67)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 104.71 (+0.67), BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), TGTX: 13.13 (-0.19), TKMR: 21.45 (-0.22), ANAC: 40.76 (-0.07), PBYI: 205.26 (+2.75), REGN: 402.40 (+0.66)
Today's Review on Biotech Equities - Vertex Pharma, Alexion Pharma, Arrowhead Research, Medivation, and Incyte
PR Newswire - Tue Feb 10, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 104.71 (+0.67), VRTX: 113.66 (+4.03), ARWR: 6.77 (+0.21), INCY: 75.94 (+0.28), ALXN: 182.29 (+6.02)
Coverage of Biotech Equities -- Amarin, Cytori Therapeutics, Medivation, Sangamo BioSciences, and Immunomedics
PR Newswire - Thu Feb 05, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Cytori Therapeutics Inc. (NASDAQ: CYTX), Medivation Inc. (NASDAQ: MDVN), Sangamo BioSciences Inc. (NASDAQ: SGMO), and Immunomedics Inc. (NASDAQ: IMMU). Free research report on Amarin can be accessed at http://get.Investor-Edge.com/pdf/?c=Amarin&am...amp;s=AMRN. The US markets on Wednesday, February 04, 2015, mostly ended on a negative note as the Dow Jones Industrial Average finished at 17,673.02, up 0.04% and the NASDAQ Composite closed at 4,716.70, down 0.23%. The S&P 500 finished the session 0.42% lower at 2,041.51. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, whereas the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
MDVN: 104.71 (+0.67), IMMU: 3.84 (unch), CYTX: 0.47 (unch), AMRN: 1.18 (unch), SGMO: 15.40 (+0.14)
Valeant Agrees To Buy Dendreon's Provenge
at Investor's Business Daily - Fri Jan 30, 10:39AM CST
Canadian drugmaker and serial acquirer Valeant Pharmaceuticals International (VRX) entered into a tentative agreement to buy the assets of bankrupt biotech Dendreon late Thursday, including Dendreon's controversial "cancer vaccine" Provenge. Valeant...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), VRX: 167.00 (-0.50), NVS: 102.20 (-0.17)
Franchise Fortunes Mark Shifts In Consensus For Marketed Products
EP Vantage - Seeking Alpha - Thu Jan 29, 3:48PM CST
Sofosbuvir is the gift that keeps on giving for Gilead Sciences (NASDAQ: GILD ). The performance of the hepatitis C franchise it has built around Sovaldi and Harvoni has had euphoric sell-side analysts giving it the biggest upgrade of any marketed...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), SNY: 49.42 (+0.82)
Insider Buys And Sells: OPKO Health, Burlington Stores
Asif Suria - Seeking Alpha - Sun Jan 25, 10:28AM CST
Welcome to edition 240 of Insider Weekends. Insider buying declined sharply last week with insiders buying just $16.43 million of stock compared to $40.18 million in the week prior. Selling on the other hand increased with insiders selling $936.53...
MDVN: 104.71 (+0.67), NOW: 77.55 (+1.60), CMC: 15.40 (+0.37), SAR: 15.78 (+0.23), OPK: 13.80 (-0.28), DAL: 44.50 (-0.31), LNG: 74.48 (+0.90), DIS: 104.17 (+0.59), BURL: 51.91 (-0.56), URI: 92.98 (+1.41)
Medivation and Astellas Report TERRAIN Data on Xtandi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 3:20PM CST
Medivation Inc. (MDVN) and partner Astellas Pharma Inc.'s (ALPMY) Xtandi met the primary endpoint in a phase II study (TERRAIN) conducted in metastatic prostate cancer patients.
MDVN: 104.71 (+0.67), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30)
Medivation's Xtandi Easily Outperforms Casodex In Key Trial
Stock Doctor - Seeking Alpha - Fri Jan 23, 11:06AM CST
I have written many articles about Medivation (NASDAQ: MDVN ) and why I believe their prostate cancer drug Xtandi (Enzalutamide) is going to be a multi-billion dollar drug. It is already being prescribed at a run rate of $1.2B in 2015. Medivation's...
MDVN: 104.71 (+0.67)
InsiderInsights.com Daily Round Up 1/22/15: SWN, CBIN, OPK, RWC
InsiderInsights - at Seeking Alpha - Fri Jan 23, 8:53AM CST
AFAM: 30.88 (+0.37), SRE: 105.56 (-1.11), SHLD: 35.70 (+2.32), OWW: 11.68 (-0.04), DLPH: 78.70 (+0.64), K: 63.20 (-0.10), MDVN: 104.71 (+0.67), NOW: 77.55 (+1.60), SNCR: 43.89 (+1.06), OPK: 13.80 (-0.28), ARR: 3.13 (unch), RWC: 5.82 (+0.06), CDNA: 6.30 (-0.14), CBIN: 27.23 (+0.08), SWN: 27.36 (+0.51), PAYC: 32.37 (-0.71)
After Yesterday's Decline of 3.90%, Medivation Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jan 22, 4:30PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $103.46 to a high of $109.60. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $105.36 on volume of 3.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MDVN: 104.71 (+0.67)
Medivation (MDVN) Weak On High Volume Today
at The Street - Thu Jan 22, 9:02AM CST
Trade-Ideas LLC identified Medivation (MDVN) as a weak on high relative volume candidate
MDVN: 104.71 (+0.67)
Xtandi successful in Phase 2 study
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 7:34AM CST
MDVN: 104.71 (+0.67), AZN: 69.96 (+0.20)
Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase in PFS as Compared to Bicalutamide in Metastatic Prostate Cancer
Marketwired - Thu Jan 22, 6:00AM CST
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced topline results from the Phase 2 TERRAIN trial comparing enzalutamide with bicalutamide in men with metastatic castration-resistant prostate cancer. The study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival (PFS) for enzalutamide compared to bicalutamide (Hazard Ratio = 0.44; 95% Confidence Interval, 0.34-0.57; p < 0.0001). Median PFS was 15.7 months in the enzalutamide group compared to 5.8 months in the bicalutamide group.
MDVN: 104.71 (+0.67)
Johnson & Johnson Finding Growth A Little Harder Now
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 21, 7:25AM CST
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18)
Johnson & Johnson Overcomes Threats from Competitors, Delivers Solid Quarterly Results
Todd Campbell, The Motley Fool - Motley Fool - Tue Jan 20, 1:01PM CST
Source: Johnson & Johnson Despite two of Johnson & Johnson 's best-selling drugs facing stiffer competition, the company still managed to deliver encouraging sales and earnings during the fourth quarter. After adjusting for currency...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00)
J&J Earnings Beat But Sales, Guidance Miss
at Investor's Business Daily - Tue Jan 20, 10:20AM CST
Medical giant Johnson & Johnson (JNJ) beat analysts' Q4 profit estimates Tuesday but missed on the topline and offered weak guidance, sending the stock down more than 3% in morning trading. J&J said that its Q4 earnings excluding one-time items rose...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00), SYK: 94.51 (+1.14)
Eli Lilly Has 'Turned The Corner,' Upgraded
at Investor's Business Daily - Thu Jan 15, 10:02AM CST
Goldman Sachs upgraded Eli Lilly (LLY) to neutral Thursday, saying the big pharma had "turned the corner" after falling hard off the patent cliff. But the investment bank downgraded Johnson & Johnson, citing increasing drug competition. "We believe...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
Look for Shares of Medivation to Potentially Pullback after Yesterday's 1.94% Rise
Comtex SmarTrend(R) - Tue Jan 13, 4:29PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $105.18 to a high of $109.99. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $105.18 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 104.71 (+0.67)
